NorthWest Biotherapeutics Inc (NWBO)

[AVII77]

Surely you did not read the paper in todays NEJM.
http://www.nejm.org/doi/full/10.1056/NEJMoa1801005

"Shiny object"?

Those results are outstanding. 50% reduction in the risk of death in first line NSCLC.

And like the DCVax trial, their trial also had x-over. And of course, efficacy was evaluated in the ITT population (non of this blended blinded stuff).

The DSMB met and stopped this trial 4 months ago and here it is published today in the NEJM.

Maybe their secret to rapid publication was they didn't have "65 authors".

I think they're trying to get so much momentum that they could advertise for Keytruda as a tried and true regimen for Cancers over this little start up NWBO without the same level of evidence.

Do you find something lacking in their "level of evidence"? It looks pretty compelling to me.
Both primary's met.
Not just "met", but blown away.

This is clearly good news for NSCLC patients.